-transparent.png){kind=logo}
Thirty-two patients (24 males, 8 females; median age 54 yrs) with recurrent and/or metastatic undifferentiated carcinoma of the nasopharyngeal type were treated with chemotherapy. Remissions were observed in 17 of 32 (53.2%) with 5 complete (CR) (15.6%) and 12 partial responses (PR) (37.6%). A combination of cisplatin and 5-fluorouracil was the most effective regimen (CR + PR = 83.3%). Objective responses. (CR + PR) were 47% (CR = 11.7%) in schemes without cisplatin and 60% (CR = 20%) in cisplatin-based combinations. The median overall duration of response was 7.2 months. The median overall survival time was 10.3 months: 15.1 months for responders and 5.2 for non-responders. No important toxicity was observed.
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
June 2022,
Head & neck,
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
December 2002,
Cancer,
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
October 1998,
Seminars in radiation oncology,
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
May 2024,
NPJ precision oncology,
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
January 2020,
Therapeutic advances in medical oncology,
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
October 2022,
Med (New York, N.Y.),
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
June 2011,
Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
April 2018,
Translational oncology,
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
September 1991,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Airoldi, and
F Pedani, and
P Gabriele, and
C Giordano, and
A Cavalot, and
V Brando
November 2023,
JAMA,
